Related Experiment Videos
Enzyme kinetics for clinically relevant CYP inhibition
1Drug Disposition, Eisai Research Institute, Andover, MA 01810, USA. zhi-yi_zhang@eri.eisai.com
Current Drug Metabolism
|June 25, 2005
Summary
In vitro studies of cytochrome P450 (CYP) enzyme inhibition are crucial for predicting clinical drug-drug interactions (DDIs). Understanding competitive inhibition and mechanism-based inactivation (MBI) helps assess DDI risks early in drug development.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Development
Background:
- In vitro cytochrome P450 (CYP) studies predict clinical drug-drug interactions (DDIs), a major hurdle in drug development.
- Advances in CYP biochemistry and gene regulation provide a scientific basis for early DDI assessment.
Purpose of the Study:
- To review the enzyme kinetics of CYP inhibitions, focusing on clinically relevant types.
- To highlight the increasing attention on mechanism-based inactivation (MBI) and its potential for causing DDIs.
Main Methods:
- Description of enzyme kinetics for various CYP inhibition types, including competitive, noncompetitive, uncompetitive, and mixed inhibition.
- Discussion of mechanism-based inactivation (MBI) and its irreversible nature.
- Analysis of unusual kinetic interactions not following Michaelis-Menten kinetics, particularly for CYP3A4.
Main Results:
- Competitive CYP inhibition is well-understood and frequently observed.
- Mechanism-based inactivation (MBI) is increasingly recognized as a significant cause of DDIs due to irreversible protein inactivation.
- Other reversible inhibitions and unusual kinetic interactions were documented for key CYP enzymes like CYP1A2, CYP2C9, and CYP3A4.
Conclusions:
- CYP inhibition studies are essential for predicting clinical DDIs.
- Reversibility and inhibitory potency, alongside therapeutic exposure, are key determinants of clinical relevance.
- In vitro evaluation of clinically relevant CYP-associated DDIs is both desirable and achievable with technological advancements.